Delivery Order SPE2DB24D2003-SPE2DB25FXLT6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $70,439.09 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme supplement) in 100-count bottles. The contract, which was competitively awarded with no set-aside designation, carries a firm fixed price and an ultimate completion date of September 3, 2025. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency awarded a $21,057.57 delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 11, 2025. AmerisourceBergen will perform this delivery order from its corporate headquarters in Conshohocken, Pennsylvania, where the company operates as a major...
- The Defense Logistics Agency awarded a delivery order valued at $1,645.28 to AmerisourceBergen Drug Corp for 24,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by May 2, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count packaging, valued at $2,254.12. This is a firm fixed-price delivery order with no set-aside designation, issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a delivery order valued at $1,101.10 to AmerisourceBergen Drug Corp on July 24, 2025, for 12,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, carrying an ultimate completion date of July 25, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply contract. This...
- The Defense Logistics Agency awarded a delivery order valued at $9,025.18 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. This firm fixed price delivery order, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 21, 2025, by the Defense Logistics Agency (DLA) for 12,000 unit capsules of Creon DR 100s, with a ceiling value of $3,643.14. This is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $4,656.29 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s, a pancreatic enzyme replacement therapy. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 29, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,860.27 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This competitive, firm fixed-price delivery order, with an ultimate completion date of September 11, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The order will be fulfilled from the...
- The Defense Logistics Agency awarded a $2,376.88 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of 36,000 unit capsules of Creon 100s, a pancreatic enzyme replacement therapy. This competitively awarded, firm fixed-price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXLT6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,385.77 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. This is a firm fixed price, non-set-aside competitive award with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a major healthcare solutions provider and pharmaceutical distributor serving federal medical procurement needs. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide, including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio demonstrates consistent capability to meet competitive procurement requirements across multiple therapeutic domains through both small-value and substantial orders.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 8/15/25 |